Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

Roche’s Perjeta regimen gets FDA priority review

Written by: | no-reply@reuters.com | Dated: Friday, September 29th, 2017

 

Roche’s Perjeta regimen gets FDA priority review in breast cancer

 

ZURICH (Reuters) – The U.S. Food and Drug Administration (FDA) has granted priority review for Roche’s Perjeta in combination with Herceptin and chemotherapy for treating HER2-positive early breast cancer after surgery, Roche said on Friday.

The FDA is expected to make a decision on approval by Jan 28, 2018, it said in a statement.

A clinical trial for the combination therapy resulted in a modest benefit for patients, but Roche has expressed confidence that Perjeta will drive sales as it tries to offset the hit from cut-price competition to top-selling biological cancer medicines.

 

Reporting by Michael Shields

 

Reuters source:

http://www.reuters.com/article/us-roche-perjeta/roches-perjeta-regimen-gets-fda-priority-review-in-breast-cancer-idUSKCN1C40H2

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2018 Focus: Agency Profiles, Manny Awards and Annual Review

Subscribe

Ad Right Bottom

Main Navigation